Selskabets formål er at drive virksomhed indenfor bioteknologi og anden dermed i forbindelse stående virksomhed, herunder udvikling, produktion og salg af diagnostiske kit samt eje datterselskaber i forbindelse hermed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 527.4 mio. | 170.8 mio. | 720.3 mio. | 230.9 mio. | 176 | |
CVR: 30511271
Compared to 50.000 companies in Ikke-finansielle holdingselskaber
Comparison is based on industry median values
Companies in the same industry and area
CVR 39839342
CVR 34703132
CVR 41489138
CVR 39350017
CVR 36944471
The financial health of NORDIC BIOSCIENCE HOLDING A/S appears strong, particularly in 2024, where it reported a revenue of 527.4 million DKK and a profit of 170.8 million DKK, indicating significant growth compared to previous years. The profit margin has improved notably, rising from 17 million DKK in 2023 to 170.8 million DKK in 2024, reflecting a robust operational performance. Equity has also increased substantially, reaching 230.9 million DKK in 2024, suggesting a solid capital position. However, the lack of revenue data for prior years raises concerns about consistency and transparency in financial reporting. Overall, the company is well-positioned within its industry, showcasing strong profitability and a healthy equity base.
AI-generated summary
companydata.dk